

Analysis of Industry 4.0 and Transformative Trends in Pharma

Dr. Mrunal Joshi^{1*}, Dr. Ritu Sinha², Dr. Maithili Dhuri³

*1*Associate Professor Ies's Management College And Research Centre, Mumbai, India.*

E-Mail: Mrunal.Joshi@Ies.Edu

2associate Professor, Ies's Management College And Research Centre, Mumbai, India.

E-Mail: Ritu.Sinha@Ies.Edu

3 Assistant Professor Ies's Management College And Research Centre, Mumbai, India.

E-Mail: Maithili.Dhuri@Ies.Edu

ARTICLE INFO

ABSTRACT

Received: 22 Sep 2024

Accepted: 24 Dec 2024

Pharma 4.0 represents a disruptive force that is revolutionizing the pharmaceutical industry. It is presenting newer opportunities for innovation, and patient-centric care. The smart manufacturing driven by advanced technologies like Artificial Intelligence (AI), Robotics, Internet of Things (IoT), Big Data Analytics (BDA) seeks to integrate digital technologies and automation to create smart, connected manufacturing facilities. The given study examined the applications of AI, big data analytics, and IoT across drug development and marketing processes. The study has used qualitative analysis through NVivo 14 to analyze the secondary data collected from white papers, industry reports, and peer-reviewed research articles. The findings suggested that data integrity, process innovation, and technology integration are critical dimensions for effective Pharma 4.0 implementation. Furthermore, strategy, technology, operations, culture, and people play crucial roles in driving this change. This study provides insights for stakeholders who want to leverage these technologies for improved efficiency and effectiveness in the pharmaceutical sector.

KEYWORDS: PHARMA 4.0, MANUFACTURING AUTOMATION, ROBOTICS, INNOVATION, ARTIFICIAL INTELLIGENCE, BIG DATA ANALYSIS, INTERNET OF THINGS (IOT), PHARMACEUTICAL INDUSTRY

INTRODUCTION

The growing discussions around the concept fourth industrial revolution, known as Industry 4.0 has gained substantial attention in recent years (Ghobakhloo, 2020; Oztemel, 2020; Massaro et al, 2021). It calls for a fundamental shift in the way the industries operate using technology. It optimizes processes, improves quality, reduces costs, and creates new opportunities for innovation and growth. Industry 4.0 centers on the ongoing automation, digitalization, and integration of technologies in various industries (Tsaramirsis et al, 2022). It encompasses the use of advanced technologies such as artificial intelligence, robotics, the Internet of Things (IoT), big data analytics, cloud computing, and augmented reality to revolutionize manufacturing and other sectors (Logeswaran et al, 2024).

The Indian pharmaceutical industry is projected to grow at a CAGR of 9 to 11% in the coming years touching \$130 billion by 2030 (Pharmaceuticals Industry Report, 2024). India has positioned itself as the world's largest supplier of generic drugs along with increasing demand for affordable healthcare solutions globally. Pharma 4.0 concept is transforming the pharmaceutical industry through the integration of advanced technologies and data-driven approaches (Arden et al, 2021; Manchadi et al, 2023; Tetteh-Caesar et al, 2024; Ullagaddi, 2024). It seeks to enhance efficiency, productivity, and innovation in pharmaceutical manufacturing and development processes.

The pharmaceutical sector faces an urgent need to adapt to Industry 4.0 due to its increasing dependence on technological innovation for maintaining competitiveness. Presently, technological superiority defines industry leaders, therefore the transition from conventional manufacturing methods to Industry 4.0 is quite significant. It presents its own set of challenges, especially for emerging economies (Samaranayake et al., 2018). Hence, there is a need to align with the vision of Industry 4.0 for pharmaceutical companies. It involves adoption of digital transformation and advanced automation. However, many organizations struggle to identify specific areas of action and fail to implement concrete strategies, programs that could drive this transition (Schumacher et al., 2016). This

lack of clarity and direction slows down the adoption of new technologies, limiting the potential for growth in the sector. Also the health information systems (HIS) play a critical role in optimizing pharmaceutical processes, as they directly impact the quality of care, cost and overall healthcare delivery (Baines et al., 2018). The implementation of advanced technologies such as data analytics, artificial intelligence, and the Internet of Things (IoT) would streamline operations, enhance precision in drug manufacturing, and more personalized healthcare solutions.

The huge demand for personalized medicines increases the pharmaceutical industry's pressure to produce new drugs (Hemanth Kumar et al., 2020a; Van den Heuvel and Stirling, 2017; Johnson et al 2021; Arief et al, 2022). The discovery of innovative drug products shows that it is necessary to develop product innovations supporting the technology capability to encourage the competitiveness of the pharmaceutical industry (Grzybowska and Łupicka, 2017; Putri et al, 2021). Implementing digital technologies throughout the pharmaceutical value chain, from R&D to production, distribution, and patient care can optimize processes and decision-making. The effective use of big data analytics, artificial intelligence, machine learning, and digital platforms can enhance the process (Salas et al, 2022; Selvaraj et al, 2021; Sarkar et al, 2023). The use of automation and robotics help streamline manufacturing processes, reduce human error, and increase productivity. The automated systems can handle repetitive tasks more efficiently, freeing up human resources for more complex and value-added activities. Implementing advanced quality assurance and compliance systems ensures product quality, safety, and regulatory compliance. This would improve real-time monitoring of manufacturing processes, automated documentation, and traceability solutions. Pharma 4.0 aims to develop tailored treatments and therapies that are more effective and safer for individual patients by using the advances in genomics, biomarkers, and digital health technologies (Algorri et al, 2022; Beg et al, 2022, Hassan et al, 2022; Afolalu et al, 2024). Digital technologies used in raw material sourcing, goods distribution and inventory management improve logistics, demand forecasting, and inventory tracking resulting in enhanced efficiency and reduced costs (Raijada et al 2021, Andreadis et al, 2022; Ullagaddi, 2024).

This study, building on the work of Danese et al. (2018), seeks to explore the changing dimensions of Industry 4.0 and its impact on the pharmaceutical sector as Pharma 4.0. It aims to identify the key themes, trends, and technological advancements presented in recent literature. It also categorizes these publications according to different stages of the research lifecycle, such as conceptualization, experimentation, and implementation. The study aims to provide strategic insights and recommendations for future research directions, offering valuable guidance for scholars looking to advance the field of Pharma 4.0.

LITERATURE REVIEW

Industry 4.0 in healthcare makes use of a range of advanced technologies like digitization, artificial intelligence, Internet of Things, machine learning, advanced computing, big data mining, and augmented reality into the manufacturing and marketing practices (Samaranayake, Ramanathan, & Laosirihongthong, 2017; Ristevski, 2018; Popov, et al., 2022; Ullagaddi, 2024). It has a potential to bring about improved drug quality, higher output, increased agility, and flexibility, enhance patient care, and drive innovation in healthcare delivery and research (Ezell, 2016; Buvailo, 2018; Baur and Wee, 2015; Clemons, 2016; Tilley, 2017). At the same time, it has its issues like the integration of IoT technologies in the pharmaceutical industry brings challenges related to data security, interoperability, and regulatory compliance (Elkhodr et al., 2016; Abounassar et al., 2022; Ullagaddi, 2024; Bhuiyan et al., 2021; Ratta et al. 2021).

INTERNET OF THINGS

The implementation of Industry 4.0 involved automation of various processes within the pharmaceutical value chain (Arden et al., 2021). For instance, Internet of Things (IoT) enabled devices like smart sensors and wearable technologies help pharmaceutical companies to track crucial parameters like temperature, humidity, and pressure (Pramanik et al., 2021) throughout the manufacturing, storage, and transportation and track the movement of drugs and medical supplies throughout the supply chain (Ristevski, 2018; Vafadar et al., 2021). Even the electronic sensors, RFID tags, and connectivity capabilities can track medication usage and dosage adherence among patients (Mason et al., 2021). IoT technologies help in collecting the real-world data and Patient Generated Health Data (PGHD) during clinical trials and research studies (Khatiwada et al. 2024). The wearable devices and mobile health

applications integrated with IoT capabilities help researchers to gain real-time insights into patient behaviour, treatment responses, and disease progression (Beg et al., 2022). This data-driven methodology improves the efficiency of clinical trials, shortens drug development timelines, and supports precision medicine initiatives (Moingeon, 2022, Obijuru et al, 2024). IoT-enabled devices and connected healthcare systems enhance patient safety by providing early detection of adverse drug reactions, medication errors, and other safety concerns (Afolalu et al, 2024).

Artificial Intelligence

Artificial Intelligence (AI) is increasingly being used in the pharmaceutical industry to modernize the drug discovery, development processes, clinical trials, and personalized medicine. AI algorithms analyse huge amounts of biological, chemical, and clinical data to identify potential drug candidates and predict their efficacy and safety profiles (Selvaraj et al, 2021, Gupta et al, 2021; Chen, 2024). These algorithms can segment patient populations, predict treatment responses, and help in designing the targeted therapies and precision medicine to individual patient (Johnson, 2021). It helps in optimizing the trial protocols, and predicting patient outcomes, and improve the success rates of clinical trials (Kimmelman et al, 2023). AI-powered platforms analyse existing drug databases, biomedical literature, and molecular data to identify potential drug repurposing opportunities for new indications and therapeutic uses (Liu et al, 2022; Obijuru et al, 2024). AI-powered pharmacovigilance systems enable early detection of safety signals, facilitate risk assessment, and support regulatory compliance, enhancing patient safety and minimizing the risks associated with pharmaceutical products. AI technologies optimize drug formulation processes, dosage forms, and manufacturing parameters to improve drug solubility, stability, and bioavailability (Kalita et al, 2024; Suriyaamporn et al, 2024).

Big Data Analytics

Big Data Analytics (BDA) analyses real-world data sources like electronic health records, claims data, and patient registries, to generate real-world evidence and support post-market surveillance efforts (Roy, 2024). It is playing an important role in personalized medicine. As the volume and complexity of healthcare data continue to grow, the researchers can use the big data analytics to come up with new therapeutic targets (Hassan et al, 2022). It can help in predicting drug-target interactions, and accelerate the drug discovery process. The analysis of patient-specific data and molecular profiles can help the healthcare providers to deliver personalized treatment regimens to individual patient characteristics, and reduce the risk of adverse events (Obijuru et al, 2024). It can be used by pharmaceutical companies to evaluate drug safety and effectiveness profiles, identify potential safety signals (Hassan et al, 2022; Salas et al, 2022). It also plays a crucial role in optimizing supply chain operations, inventory management, and distribution processes, enhancing drug quality and safety throughout the pharmaceutical supply chain (Nguyen et al, 2022).

Digital Manufacturing

Digital Manufacturing offers innovative solutions to enhance drug development, manufacturing efficiency, and product quality (Nguyen et al, 2022; Andreadis et al, 2022). The digital manufacturing technologies like robotics and automation solution help in streamline pharmaceutical manufacturing processes, reducing human error and improving process consistency (Nunavath et al, 2024). The advanced material processing techniques like continuous manufacturing, 3D printing, and nanotechnology, help in ensuring product quality and compliance with regulatory standards (Jain et al, 2021). By leveraging these digital manufacturing technologies, pharmaceutical companies can minimize batch-to-batch variability and reduce manufacturing costs (Grangeia et al, 2020). The advanced materials processing technologies help in the development of innovative drug delivery systems and personalized medicine approaches like sustained release formulations, and enhanced treatment adherence (Raijada et al, 2021). The continuous manufacturing offers advantages like reduced production lead times, increased production flexibility, and enhanced scalability (Algorri et al, 2022). The digital manufacturing generates vast amounts of data from manufacturing equipment, sensors, and production processes (Ganesh et al, 2020). The pharmaceutical companies can analyse manufacturing data in real-time, identify process inefficiencies, and address quality issues before they impact product quality or patient safety (Leal et al, 2021).

In biomedicine, machine learning and deep learning are used to simulate human knowledge (Gupta et al, 2021; Sarkar, et al 2023). It can also be used for medical image processing for accurate decisions (Pillai, 2021). For instance, 3D printing is used for additive manufacturing of patient-specific metal/ceramics implants; for individual surgeons' tool designs and many more. Virtual Reality is transforming healthcare and changing the way patients are being treated (Vashishth et al, 2023). It is offering safe and efficient treatment for pain and a powerful rehabilitation instrument for anxiety, post-traumatic syndrome, stress, strokes (Paiva, et al, 2024). Healthcare professionals and medical students use VR simulations for improving their skills and for complex surgery planning (Desselle et al, 2020).

RESEARCH METHODOLOGY

The study adopted a qualitative descriptive research design aimed to identify the drivers and challenges for the effectiveness of Pharma 4.0. The existing academic literature and industry reports were used to conceptualize the variables. The data was collected from various sources including media reports, industry reports, white papers, working papers, research articles, review papers, and policy papers. These different sources were adopted to ensure the examination of the research topic from multiple perspectives. Various delimitations and filtration criterias were applied to select the 46 relevant research papers for the study (Table 1).

Table 1: Selection Criteria of Research Papers

9103 - Scholarly Journals, Full Text	Inclusion – Scholarly Journals, Full Text Only, Peer Reviewed Time Frame to select the latest work in Language English
8757 - Peer Reviewed	
8106 - Last 10 Years	
5625 - Last 5 Years	
463 - Last 12 Months, English	
449- Articles after exclusion of evidence based, correspondence etc.	Exclusion- Filters are applied on Subject – Evidence Based, Correspondence, Communication, Conference Proceedings, Editorials were excluded Filters are applied on publication titles to select the relevant stream related to management and social science rather than scientific process oriented papers.
153 - After filters on subjects	
150 - After excluding conference Papers, correspondence etc.	
46 - After filters on publication titles	

This was followed by 13 in-depth interviews with the industry experts to confirm the drivers and challenges of Pharma 4.0. Further, Nvivo 14, a qualitative data analysis software was used for content analysis.

The data analysis technique used in this study followed the approach suggested by Bungin (2012). This approach guided various stages of data analysis like data reduction, data display, and drawing conclusions. The process of data reduction consisted of summarizing the collected data, coding relevant segments, tracing themes, making clusters of related information, and writing memos to capture insights and reflections. The qualitative data was further presented in descriptive form using matrices, diagrams, tables, and charts. These visual representations helped in explaining the patterns, relationships, and themes within the data. The conclusions drawn from the analysis was verified and confirmed through interpretation activities. This involved comparing findings with existing literature, getting feedback from pharma industry experts. This helped in examining the consistency and coherence of the results. The coding process in this study was based on the principles of the Rooting Theory research method.

After the data collection, NVivo software was used to initiate the coding process making use of a textual hierarchy. The primary and secondary headings within the text were systematically coded into parent and child nodes. After the comparison, similar parent or child nodes were consolidated, and further categorized on the themes of the parent nodes. After the text-codes, node names and positions were adjusted to align with their corresponding textual content. The utilization rate of each textual content was analyzed utilizing NVivo's coding coverage statistics. The software helped in ensuring the systematic approach to data analysis, thereby enhancing the reliability of the findings. The inter-coder reliability was used by involving multiple researchers in the coding process (Bungin, 2012; Allsop et al, 2022). All these measures had helped to contribute to the overall trustworthiness of the study.

RESULTS

The understanding of Pharma 4.0 from qualitative data defined the concept as the integration of intelligent digital technologies into manufacturing and industrial processes. It encompassed technologies like industrial IoT networks, AI, Big Data, robotics, and automation. The analysis of research papers showed that it improved productivity & efficiency, flexibility, agility, and increased profitability. Industry 4.0 also improved the patient experience, including more personalized and intelligent products and services.

The frequency analysis of keywords (Fig 1) extracted from industry reports, research papers, and interviews revealed the theme words - data, digital, systems, digital transformation and technology. This inferred that Pharma 4.0 can be effective with the integration of technology into work processes.




Fig 1: High-Frequency Words from Literature

These keywords were further discussed with industry experts in the context of emerging trends in pharmaceuticals industry. The interview transcripts were analysed with qualitative software Nvivo that identified the use of technology as a main theme in Pharma 4.0. The word cloud (Fig 2) generated from the transcripts emphasized on data, digitization, technology, processing (automation), systems and use of analytics.



The treemap displays the following categories and their sub-topics:

- data**
 - big data
 - data...
 - data...
 - data...
 - cli...
 - advan...
- process**
 - proce...
 - dr...
 - manuf...
 - cog...
 - ad...
 - drug...
 - strea...
 - appr...
- systems**
 - regu...
 - pro...
 - cl...
 - asse...
 - cybe...
 - sma...
- drug**
 - drug...
 - incl...
 - dr...
 - dr...
 - strea...
 - drug...
- manufacturing**
 - man...
 - agi...
 - sma...
 - ma...
- technology**
 - digital
 - tec...
 - tec...
 - advan...
- management**
 - 21s...
 - lean m...
 - green ...
 - stakeh...
 - pro...
- supply chain**
- research**
 - fu...
 - suff...
- pharmaceuticals**
 - pha...
- digital**
 - digital ...
 - digital ...
 - digital ...
- information**
 - pub...
- development**
 - dr...
- operations**
- real-time**
- industry**
 - pha...
- networks**
 - neu...

The further analysis of literature helped in identifying the key dimensions of Pharma 4.0 implementation (Table 2). These dimensions provide a great help to understand the role of strategic leadership for mapping the organizational needs and technology. The right understanding of technology at every level of organization, right from leadership roles, managers, and employees to customers leads to successful adoption, implementation and execution. They provided lead pointers to explore the phenomenon further. The literature indicated the use of technology is an innovative move, and hence diffusion of innovation theory can be explored as future research direction.

Dimension	Description
1. Strategy	Implementation of IV4.0 roadmap, Availability of resources for realization, Adaption to business models
2. Leadership	Willingness of leaders, Management competences and methods

3. Operations	Decentralization of processes, Automation, Modelling and Simulation, interdisciplinary, Interdepartmental Collaboration, Value of ICT in company
4. Technology	Existence of modern ICT, Utilization of mobile devices, Machine to Machine communication
5. Culture	Knowledge sharing, Open-innovation and cross company collaborations, value of ICT in company
6. People	Openness of employees to new technology, autonomy of employees, ICT competence of employees
7. Governance	Suitability of technology standards, protection of IPR, Labor regulations for IV4.0
8. Customers	Utilization of customer data, digitization of sales/service, customer's digital media competence

An attempt was made to explore the sentiments regarding the use of technology in the selected literature. The extant research discussed the use of technology but it remained at an exploratory phase.




Fig 4: Sentiment Analysis of Literature

Sentiment			
⊕ Name	⇄ Files	References	
⊕ Positive	47	5916	
⊕ Very positive	47	1305	
⊕ Moderately po	47	4611	
⊖ Negative	47	3281	
⊖ Moderately ne	47	2361	
⊖ Very negative	47	920	

Fig 5: Sentiment Tokens

While the reviewed research papers expressed some positive sentiments, the majority of the articles adopted a neutral tone (Fig 4 & Fig 5) leading to the inference that the concept is still in its nascent phase and yet to attain maturity.

The positive sentiments hinted at the potential use of technology and the benefits that could be achieved through the implementation of the right solutions (Fig 6). It was anticipated that additional use cases would drive further automation and facilitate the integration of technology with other platforms.




Fig 6: Snapshot of Positive Sentiments hinting the user expectations

Negative Sentiments are appearing to be mainly out of the insecurity of jobs and non-clarity on strategic roadmap (Fig 7). The leadership role becomes very important in this situation. The governance framework will be playing a great role for industry specific acceptance and adoption thereafter.




Fig 7: Snapshot of Negative Sentiments hinting the user insecurity

Discussion

Pharmaceutical companies are adopting emerging technologies to stay ahead and meet the demands of the competitive healthcare sector. Artificial Intelligence (AI) is revolutionizing healthcare by enabling more accurate diagnosis, personalized treatment plans, and efficient drug discovery processes. It is also enhancing patient care through predictive analytics, early disease detection, and improved decision-making, ultimately transforming the way healthcare is delivered. The integration of automated systems and robotics in pharmaceutical manufacturing, packaging, and distribution processes is significantly enhancing efficiency and precision. Automation reduces human error and speeds up production, ensuring consistent product quality and faster turnaround times. Additionally, robotics in packaging and distribution optimizes workflow, increases safety, and allows for greater scalability in meeting market demands. To accelerate drug discovery, the pharmaceutical companies are leveraging big data analytics and predictive modeling for identifying the promising compounds. These technologies optimize clinical trials by predicting patient responses and improving trial design. Additionally, they enable personalized medicine by analyzing vast datasets to tailor treatments to individual patient profiles, enhancing efficacy and reducing side effects. The implementation of blockchain technology in the pharmaceutical supply chain enhances

transparency, traceability, and security by providing a secure, immutable ledger for recording transactions. This technology allows companies to track the provenance of raw materials, ensuring that they meet quality standards and are ethically sourced. Additionally, blockchain helps combat counterfeit drugs by enabling real-time verification of products at every stage of the supply chain, from production to distribution, ensuring that only genuine medications reach patients.

Industry 4.0 technologies are driving the shift towards patient-centric healthcare by enabling real-time remote patient monitoring, facilitating personalized digital therapeutics, and expanding access through telemedicine. These advancements enhance patient engagement, improve treatment outcomes, and provide more tailored and accessible healthcare solutions. 3D printing technology is revolutionizing personalized medicine by allowing for the customization of dosage forms tailored to individual patient needs, such as specific drug combinations or dosages. It also enables the rapid prototyping of innovative drug delivery systems, accelerating the development of new treatments. This technology ensures more precise and effective therapies, enhancing patient outcomes.

Industry 4.0 technologies also enable pharmaceutical companies to adopt sustainable practices by leveraging data analytics and automation to optimize energy consumption, reduce waste, and enhance manufacturing efficiency. Advanced monitoring and control systems help minimize resource usage and emissions, contributing to environmentally friendly operations.

Although Industry 4.0 is bringing transformative changes in pharmaceutical industry a careful approach is required about the technology adoption since the pharmaceutical industry involves significant regulatory challenges and compliance requirements. Data privacy is crucial, as pharmaceutical companies must adhere to regulations like GDPR and HIPAA to protect patient information. Cybersecurity is another major concern, requiring robust measures to safeguard sensitive data from breaches and cyberattacks. Additionally, the validation of digital systems is essential to ensure they meet stringent regulatory standards, such as those set by the FDA, to confirm their accuracy, reliability, and compliance in manufacturing and data management processes.

CONCLUSIONS

Pharmaceutical companies are adapting to new technological trends to stay competitive and meet the evolving demands of the healthcare sector. With advancements in artificial intelligence, machine learning, and big data analytics, these companies are now able to streamline drug discovery processes, personalize medicine, and improve patient outcomes. The integration of digital health technologies, such as wearable devices and telemedicine, is also enabling pharma companies to collect real-time data and enhance patient engagement. Additionally, blockchain technology is being explored to ensure the security and transparency of the supply chain, while 3D printing is opening up new possibilities for customized drug formulations. As the industry continues to innovate, pharma companies are investing in technology to not only improve operational efficiency but also to deliver more effective and targeted therapies to patients. In the manufacturing sector, there is an ongoing experimentation with drug management and media processes. They are aimed at enhancing efficiency and product quality. Companies are exploring new methods for drug formulation and delivery, while testing innovative media compositions to optimize cell culture and bioprocessing. These efforts are crucial in improving production scalability, reducing costs, and ensuring the consistent quality of pharmaceuticals. Although the focus is increasingly on the automation of services, this shift is expected to bring positive long-term benefits. Automation will streamline processes, reduce human error, and increase operational efficiency, ultimately leading to improved service quality and faster delivery times. Over time, these advancements will not only enhance productivity but also create opportunities for more strategic, high-value work, allowing companies to adapt and thrive in a rapidly evolving market.

REFERENCES

- [1] Abounassar, E. M., El-Kafrawy, P., & Abd El-Latif, A. A. (2022). Security and interoperability issues with internet of things (IoT) in healthcare industry: A survey. *Security and privacy preserving for IoT and 5G networks: techniques, challenges, and new directions*, 159-189.
- [2] Allsop, D. B., Chelladurai, J. M., Kimball, E. R., Marks, L. D., & Hendricks, J. J. (2022). Qualitative methods with Nvivo software: A practical guide for analyzing qualitative data. *Psych*, 4(2), 142-159.
- [3] Afolalu, O. O., Afolalu, S. A., Afolalu, O. F., & Akpor, O. A. (2024,). Internet of Things and Software Applications in Patient Safety Adverse Event Detection and Reporting: A Comprehensive Literature Review. In 2024 International Conference on Science, Engineering and Business for Driving Sustainable Development Goals (SEB4SDG) (pp. 1-11). IEEE.
- [4] Algorri, M., Abernathy, M. J., Cauchon, N. S., Christian, T. R., Lamm, C. F., & Moore, C. M. (2022). Re-envisioning pharmaceutical manufacturing: increasing agility for global patient access. *Journal of Pharmaceutical Sciences*, 111(3), 593-607.
- [5] Andreadis, I. I., Gioumouxouzis, C. I., Eleftheriadis, G. K., & Fatouros, D. G. (2022). The advent of a new era in digital healthcare: a role for 3D printing technologies in drug manufacturing?. *Pharmaceutics*, 14(3), 609.
- [6] Arden, N. S., Fisher, A. C., Tyner, K., Lawrence, X. Y., Lee, S. L., & Kopcha, M. (2021). Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. *International Journal of Pharmaceutics*, 602, 120554.
- [7] Arief, N. N., Gustomo, A., Roestan, M. R., Putri, A. N. A., & Islamiaty, M. (2022). Pharma 4.0: analysis on core competence and digital levelling implementation in pharmaceutical industry in Indonesia. *Heliyon*, 8(8).
- [8] Baines, R. (2018). Quality improvement as the goal of medical leadership. In *Medical Leadership* (pp. 16-21). Routledge.
- [9] Baur, C., & Wee, D. (2015). Manufacturing's next act. McKinsey & company, 6, 1-5.
- [10] Beg, S., Handa, M., Shukla, R., Rahman, M., Almallki, W. H., Afzal, O., & Altamimi, A. S. A. (2022). Wearable smart devices in cancer diagnosis and remote clinical trial monitoring: Transforming the healthcare applications. *Drug discovery today*, 27(10), 103314.
- [11] Bhattacharya, S., & Pandey, M. (2021). Issues and Challenges in Incorporating the Internet of Things with the Healthcare Sector. *Data Engineering and Communication Technology: Proceedings of ICDECT 2020*, 639-651.
- [12] Bhuiyan, M. N., Rahman, M. M., Billah, M. M., & Saha, D. (2021). Internet of things (IoT): A review of its enabling technologies in healthcare applications, standards protocols, security, and market opportunities. *IEEE Internet of Things Journal*, 8(13), 10474-10498.
- [13] Bungin, B. (2012). *Qualitative Research Methodology: Methodological Actualization Towards a Variety of Contemporary Variants*.
- [14] Buvailo, A. (2018). How big pharma adopts AI to boost drug discovery. Retrieved April, 27, 2020.
- [15] Chen, X. (2024). AI and Big Data: Leveraging Machine Learning for Advanced Data Analytics. *Advances in Computer Sciences*, 7(1).
- [16] Clemons, E. K., Wilson, J., Matt, C., Hess, T., Ren, F., Jin, F., & Koh, N. S. (2016). Global differences in online shopping behavior: Understanding factors leading to trust. *Journal of Management Information Systems*, 33(4), 1117-1148.
- [17] Danese, P., Manfè, V., & Romano, P. (2018). A systematic literature review on recent lean research: state-of-the-art and future directions. *International Journal of Management Reviews*, 20(2), 579-605.
- [18] De Alwis, A. M. L., De Silva, N., & Samaranayake, P. (2024). Industry 4.0-enabled sustainable manufacturing: current practices, barriers and strategies. *Benchmarking: An International Journal*, 31(6), 2061-2089.
- [19] Desselle, M. R., Brown, R. A., James, A. R., Midwinter, M. J., Powell, S. K., & Woodruff, M. A. (2020). Augmented and virtual reality in surgery. *Computing in Science & Engineering*, 22(3), 18-26.

- [20] Elkhodr, M., Shahrestani, S., & Cheung, H. (2016). The internet of things: New interoperability, management and security challenges. arXiv preprint arXiv:1604.04824.
- [21] Ezell, W. (2017). Length of Stay and Reimbursement Rates for Medicare Patients.
- [22] Ganesh, S., Su, Q., Nagy, Z., & Reklaitis, G. (2020). Advancing smart manufacturing in the pharmaceutical industry. In *Smart Manufacturing* (pp. 21-57). Elsevier.
- [23] Ghobakhloo, M. (2020). Industry 4.0, digitization, and opportunities for sustainability. *Journal of cleaner production*, 252, 119869.
- [24] Grangeia, H. B., Silva, C., Simões, S. P., & Reis, M. S. (2020). Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives. *European journal of pharmaceuticals and Biopharmaceutics*, 147, 19-37.
- [25] Grzybowska, K., & Łupicka, A. (2017). Key competencies for Industry 4.0. *Economics & Management Innovations*, 1(1), 250-253.
- [26] Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021). Artificial intelligence to deep learning: machine intelligence approach for drug discovery. *Molecular diversity*, 25, 1315-1360.
- [27] Hassan, M., Awan, F. M., Naz, A., deAndrés-Galiana, E. J., Alvarez, O., Cernea, A., ... & Kloczkowski, A. (2022). Innovations in genomics and big data analytics for personalized medicine and health care: A review. *International journal of molecular Sciences*, 23(9), 4645.
- [28] Jain, K., Shukla, R., Yadav, A., Ujjwal, R. R., & Flora, S. J. S. (2021). 3D printing in development of nanomedicines. *Nanomaterials*, 11(2), 420.
- [29] Johnson, K. B., Wei, W. Q., Weeraratne, D., Frisse, M. E., Misulis, K., Rhee, K., ... & Snowden, J. L. (2021). Precision medicine, AI, and the future of personalized health care. *Clinical and translational science*, 14(1), 86-93.
- [30] Kalita, M. J. K., Bora, M. G., Mohan, M. H. R., & Das, P. J. (2024). Innovations in Pharmacovigilance: Harnessing AI for Enhancing Drug Safety and Efficacy. *Modern Trends in Multi-Disciplinary Research (Vol-1)*.
- [31] Khatiwada, P., Yang, B., Lin, J. C., & Blobel, B. (2024). Patient-Generated Health Data (PGHD): Understanding, Requirements, Challenges, and Existing Techniques for Data Security and Privacy. *Journal of Personalized Medicine*, 14(3), 282.
- [32] Kimmelman, J., Mandel, D. R., & Benjamin, D. M. (2023). Predicting Clinical Trial Results: A Synthesis of Five Empirical Studies and Their Implications. *Perspectives in Biology and Medicine*, 66(1), 107-128.
- [33] Kumar, S. H., Talasila, D., Gowrav, M. P., & Gangadharappa, H. V. (2020). Adaptations of Pharma 4.0 from Industry 4.0. *Drug Invention Today*, 14(3).
- [34] Leal, F., Chis, A. E., Caton, S., González-Vélez, H., García-Gómez, J. M., Durá, M., ... & Mier, M. (2021). Smart pharmaceutical manufacturing: ensuring end-to-end traceability and data integrity in medicine production. *Big Data Research*, 24, 100172.
- [35] Liu, Z., Chen, X., Carter, W., Moruf, A., Komatsu, T. E., Pahwa, S., ... & Tong, W. (2022). AI-powered drug repurposing for developing COVID-19 treatments. *Reference Module in Biomedical Sciences*.
- [36] Logeswaran, K., Savitha, S., Suresh, P., Prasanna Kumar, K. R., Gunasekar, M., Rajadevi, R., ... & Jayasurya, A. S. (2024). Unifying Technologies in Industry 4.0: Harnessing the Synergy of Internet of Things, Big Data, Augmented Reality/Virtual Reality, and Blockchain Technologies. *Topics in Artificial Intelligence Applied to Industry 4.0*, 127-147.
- [37] Manchadi, O., Ben-BOUAZZA, F. E., Dehbi, Z. E. O., Said, Z., & Jioudi, B. (2023). Towards Industry 4.0: An IoT-Enabled Data-Driven Architecture for Predictive Maintenance in Pharmaceutical Manufacturing. In *International Conference on Advanced Intelligent Systems for Sustainable Development* (pp. 28-45). Cham: Springer Nature Switzerland.
- [38] Mason, M., Cho, Y., Rayo, J., Gong, Y., Harris, M., & Jiang, Y. (2022). Technologies for medication adherence monitoring and technology assessment criteria: narrative review. *JMIR mHealth and uHealth*, 10(3), e35157.
- [39] Massaro, M., Secinaro, S., Dal Mas, F., Brescia, V., & Calandra, D. (2021). Industry 4.0 and circular economy: An exploratory analysis of academic and practitioners' perspectives. *Business Strategy and the Environment*, 30(2), 1213-1231.
- [40] Moingeon, P., Kuenemann, M., & Guedj, M. (2022). Artificial intelligence-enhanced drug design and development: Toward a computational precision medicine. *Drug discovery today*, 27(1), 215-222.

- [41] Nguyen, A., Lamouri, S., Pellerin, R., Tamayo, S., & Lekens, B. (2022). Data analytics in pharmaceutical supply chains: state of the art, opportunities, and challenges. *International Journal of Production Research*, 60(22), 6888-6907.
- [42] Nunavath, R. S., & Nagappan, K. (2024). Future of Pharmaceutical Industry: Role of Artificial Intelligence, Automation and Robotics. *Journal of Pharmacology & Pharmacotherapeutics*, 15(2).
- [43] Obijuru, A., Arowoogun, J. O., Onwumere, C., Odilibe, I. P., Anyanwu, E. C., & Daraojimba, A. I. (2024). Big data analytics in healthcare: a review of recent advances and potential for personalized medicine. *International Medical Science Research Journal*, 4(2), 170-182.
- [44] Oztemel, E., & Gursev, S. (2020). Literature review of Industry 4.0 and related technologies. *Journal of intelligent manufacturing*, 31(1), 127-182.
- [45] Paiva, H. W. A., Golçalves, J. G., Rodrigues, D. Z., & Rosa, R. L. (2024). A Comprehensive Analysis of Virtual Reality Applications in Healthcare. *INFOCOMP Journal of Computer Science*, 23(1).
- [46] Pillai, A. S. (2021). Utilizing Deep Learning in Medical Image Analysis for Enhanced Diagnostic Accuracy and Patient Care: Challenges, Opportunities, and Ethical Implications. *Journal of Deep Learning in Genomic Data Analysis*, 1(1), 1-17.
- [47] Pharmaceuticals Industry Report, 2024, IBEF, Retrieved from <https://www.ibef.org/industry/pharmaceutical-india>, Sept 29, 2024
- [48] Popova, P., Petrova, M., Popov, V., & Marinova, K. (2022, October). Internet of Things as a key technology for developing smart tourism destinations. In *2022 IEEE 9th International Conference on Problems of Infocommunications, Science and Technology (PIC S&T)* (pp. 151-156). IEEE.
- [49] Pramanik, P. K. D., Upadhyaya, B. K., Pal, S., & Pal, T. (2019). Internet of things, smart sensors, and pervasive systems: Enabling connected and pervasive healthcare. In *Healthcare data analytics and management* (pp. 1-58). Academic Press.
- [50] Putri, A. N. A., Arief, N. N., Gustomo, A., & Roestam, M. R. (2021). Assessing competency and sub-competency for pharmaceutical 4.0-a Delphi study. *Polish Journal of Management Studies*, 23(2), 421-436.
- [51] Rajada, D., Wac, K., Greisen, E., Rantanen, J., & Genina, N. (2021). Integration of personalized drug delivery systems into digital health. *Advanced drug delivery reviews*, 176, 113857.
- [52] Ratta, P., Kaur, A., Sharma, S., Shabaz, M., & Dhiman, G. (2021). Application of blockchain and internet of things in healthcare and medical sector: applications, challenges, and future perspectives. *Journal of Food Quality*, 2021(1), 7608296.
- [53] Ristevski, B., & Chen, M. (2018). Big data analytics in medicine and healthcare. *Journal of integrative bioinformatics*, 15(3), 20170030.
- [54] Roy, V. (2024). Role of Electronic Medical Records, Insurance Claims Data, Distributed Data Networks and Social Media in Signal Analysis. In *Signal Analysis in Pharmacovigilance* (pp. 44-72). CRC Press.
- [55] Salas, M., Petracek, J., Yalamanchili, P., Aimer, O., Kasthuril, D., Dhingra, S., ... & Bostic, T. (2022). The use of artificial intelligence in pharmacovigilance: a systematic review of the literature. *Pharmaceutical medicine*, 36(5), 295-306.
- [56] Samaranayake, P., Ramanathan, K., & Weerabahu, W. M. S. K. (2024). Prioritisation and causal relationships of industry 4.0 readiness determinants: empirical validation of an assessment framework. *Journal of Manufacturing Technology Management*, 35(1), 1-28.
- [57] Sarkar, C., Das, B., Rawat, V. S., Wahlang, J. B., Nongpiur, A., Tiewsoh, I., ... & Sony, H. T. (2023). Artificial intelligence and machine learning technology driven modern drug discovery and development. *International Journal of Molecular Sciences*, 24(3), 2026.
- [58] Selvaraj, C., Chandra, I., & Singh, S. K. (2021). Artificial intelligence and machine learning approaches for drug design: Challenges and opportunities for the pharmaceutical industries. *Molecular diversity*, 1-21.
- [59] Suriyaamporn, P., Pamornpathomkul, B., Patrojanasophon, P., Ngawhirunpat, T., Rojanarata, T., & Opanasopit, P. (2024). The Artificial Intelligence-Powered New Era in Pharmaceutical Research and Development: A Review. *AAPS PharmSciTech*, 25(6), 188.
- [60] Tetteh-Caesar, M. G., Gupta, S., Salonitis, K., & Jagtap, S. (2024). Implementing Lean 4.0: a review of case studies in pharmaceutical industry transformation. *Technological Sustainability*.
- [61] Tilley, J. (2017). Automation, robotics, and the factory of the future. *McKinsey & Company*, 67(1), 67-72.

- [62] Tsaramirsis, G., Kantaros, A., Al-Darraj, I., Piromalis, D., Apostolopoulos, C., Pavlopoulou, A., ... & Khan, F. Q. (2022). A modern approach towards an industry 4.0 model: From driving technologies to management. *Journal of Sensors*, 2022(1), 5023011.
- [63] Ullagaddi, P. (2024). Digital transformation in the pharmaceutical industry: Enhancing quality management systems and regulatory compliance. *International Journal of Health Sciences*, 12(1), 31-43.
- [64] Vafadar, A., Guzzomi, F., Rassau, A., & Hayward, K. (2021). Advances in metal additive manufacturing: a review of common processes, industrial applications, and current challenges. *Applied Sciences*, 11(3), 1213.
- [65] Van den Heuvel, R., Kapadia, A., Stirling, C., & Zhou, J. (2018). Medical devices 2030. KPMG Int.
- [66] Vashishth, T. K., Sharma, V., Sharma, K. K., Kumar, B., Chaudhary, S., & Panwar, R. (2023). Virtual Reality (VR) and Augmented Reality (AR) Transforming Medical Applications. In *AI and IoT-Based Technologies for Precision Medicine* (pp. 324-348). IGI Global.